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0 . 4 .  List variables to be included ( I f a  qualitative study, describe types of inforrrzatiorz to be 
collected) 
Age, Sex, Race, Location (Health Planning Regions); 
Chronic Comorbidities Comorbidities (Cancer, Cardiovascular Disease, Renal Disease, Liver 
Disease, Diabetes, COPD, and Cerebrovascular Degeneration); 
Constituent Conditions (CHF; Valvular, Pulmonary Circulation, Peripheral Vascular, Liver, 
Peptic Ulcer and Chronic Pulmonary diseases; Paralysis and other Neurological Disorders; 
Diabetes, Hypothyroidism, Renal Failure, AIDS, Lymphoma, Metastatic Cancer, Tumor, 
Rheumatoid Arthritis, Coagulopathy, Obesity, Weight Loss, Fluid and Electrolyte disorders, 
Chronic blood loss anemia, Deficiency anemias, Alcohol abuse, Drug abuse, Psychoses, 
Depression, and Hypertension) 
D.5. Describe nzethods to be used for data analysis ( I f a  qualitative study, describe general 
approach to conzpiling the information collected) 
I will use available pertinent statistical software such as SPSS 13.0 for all analysis. The 
data is most efficiently imported and coded with a specialized SAS package called Comorbidity 
Software 3.0 from HCUP. 
Descriptive analysis: prevalence and means 
Chi-square and 95%CI: testing for significant trends from 2001 to 2004 
Binary logistic regression: to analyze how certain demographic subcategories and 
constituent conditions produce risk for comorbid diagnosis 
E. ANTICIPATED RESULTS: 
Over the period of 1990-2001 Virginia mirrors the rising national prevalence of many 
chronic conditions, many represented by the a high prevalence in the 45+ demographic.'32 
Furthermore, it is expected that afflicted seniors more often have multiple chronic conditions 
(comorbidities) as compared to all other ages. It is also expected that comorbidity will vary by 
racelethnicity and sex for different conditions due to existing disparities in prevention, access to 
and policy for health care. 
F. SIGNIFICANCE OF PROJECT TO PUBLIC HEALTH: 
Chronic conditions represent a significant number of preventable hospitalizations and 
huge draw on the U.S. economy. Comorbidity is currently of popularity with the VDH and state 
government and it is important to analyze yet unstudied perspectives for possible future policy 
formulation (health insurance, payment and programs). This data set (200 1 and 2004) provides 
the researcher with the very relevant opportunity to investigate current prevalence and trends for 
common comorbidities in Virginia. As long term care for chronic conditions will continue to 
heavily impact Virginia and U.S. healthcare, obtaining a grasp of these conditions will be of 
utmost importance to policy, intervention and prevention programs of the near future. 
G. IRB Status: 
1) Do you plan to collect data through direct intervention or interaction with human 
subjects? y e s  X no 
2) Will you have access to any existing identifiable private information? y e s  X no 
' Kaiser Family Foundation (KFF): State Health Facts: Virginia 2002. 
2 Behavioral Risk Factor Surveillance System Survey (BRFSS) Data, 2002. 
MPH Research Project Agreement Form 
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If you answered "no" to both of the questions above, IRB review is not required. 
Please indicate your IRB status: 
X IRB approval not required - 
- 
H. PROPOSED SCHEDULE: Start Date: 22 APR 2005 End Date: 1 JUL 2005 
I. INDICATE WHICH OF THE FOLLOWING AREAS OF PUBLIC HEALTH 
KNOWLEDGE WILL BE DEMONSTRATED: 
1. Biostatistics - collection, storage. retrieval, analysis and interpretation of health data: design and 
analysis of health-related surveys and experiments; and concepts and practice of statistical data 
analysis. A y e s  n o  (if yes, briefly describe): This data set will be analyzed in a 
cross-sectional way for comparing and contrasting trends, rates, ratios, and prevalence among 
various demographic breakdowns. 
2. Epidemiology - distributions and determinants of disease, disabilities and death in human 
populations; the characteristics and dynamics of human populations; and the natural history of disease 
and the biologic basis of health. X yes n o  (if yes, briefly describe): As this 
investigation is looking at comorbidities, it is expected that there will be a presentation of 
morbidity and mortality rates for various chronic conditions as well as there distribution 
across demographic profiles and background determinants. 
3. Environmental Health Sciences - environmental factors including biological, physical and 
chemical factors which affect the health of a community. yes _lS__no (if yes, briefly 
describe): 
4. Health Services Administration - planning, organization, administration, management. evaluation 
and policy analysis of health programs. 
- yes X n o  (if yes, briefly describe): 
5. Social/Behavioral Sciences - concepts and methods of social and behavioral sciences relevant to 
the identification and the solution of public health problems. X yes n o  (if yes, briefly 
describe): In so much as social and behavioral epidemiology describe certain prevalence of 
comorbidities in certain demographics, those will be researched and described. 
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Statement of Purpose 
The aim of this study is to categofize the type and prevalence of comorbid chronic disease in 
Virginia's adult population with respect to the following demographics: sex (Male or Female), 
age (45 years and older), race (White, Black and Other), and location (five state-defined Health 
Planning Regions) during the years 2001 (all 4 quarters) and 2004 (first 3 quarters). Due to the 
lack of state-specific descriptive studies on the interaction of chronic conditions, or chronic 
comorbidities, the Commonwealth stands to benefit from information that could lead to 
improvements in public health outcomes. 
Abstract 
Objective: Chronic disease comor%idities, on the rise in the U.S. and Virginia, represent a new 
challenge to the way medicine is practiced and prescribed. This descriptive study uses Virginia 
hospital discharge data to describe the prevalence and trends of chronic disease comorbidities 
present in the state's over-45 population during the years 2001 and 2004 
Methods: Data collected by Virginia Health Information was utilized. Adults over the age of 45 
years and who selected for race and location were included in this analysis, with an aggregate 
sample size of 813,336 (N=458,593 [2001]; N=364,743 [2004]). Pearson chi-square analyses 
determined significant sample population differences with respect to age, race, sex, location, 
number of diagnoses (up to 9) and number of chronic comorbid conditions (up to 7). Binary 
logistic regression predicted odds ratios (ORs) for these comorbid conditions across 
demographic variables. SPSS 13.0 was used for all analysis. 
Results: Chronic comorbidities and their component conditions increased in Virginia's inpatient 
population from 2001 to 2004. Chronic cardiovascular disease (CCV), chronic liver disease 
(CLV), chronic renal disease (CRN), chronic pulmonary disease (COP), and cerebrovascular 
degeneration (CCE) comorbidities all increased in diagnoses prevalence (0.3% - 1.8%), while 
cornorbid cancer (CCA) remained constant at 7.4% and cornorbid diabetes (CDI) decreased 
0.6%. Mean comorbid diagnoses increased with age. Demographic factors (race, sex, age and 
location) as well as certain constituent conditions were predictive of one or more comorbidities. 
Conclusions: In general, the findings of this report complement current chronic disease 
monitoring data for the Commonwealth of Virginia. While expected comorbidities did exist (e.g. 
obesity with diabetes), unpredicted findings such as the highly-comorbid "fluid and electrolyte 
disorders" or the high1 y-comorbid "deficiency anemias" were also noted. 
Introduction 
Chronic comorbidity is the occurrence of ostensibly unrelated chronic diseases and 
reflects the aggregate effect of all clinical conditions in a given Comorbid chronic 
diseases comprise an increasing number of preventable hospitalizations and a considerable draw 
on the U.S. economy.3 Almost every family in the nation is adversely affected by chronic 
disease, either through the direct burden of the illness or through the indirect hardships of long- 
term care. Heart disease, cancer, asthma and diabetes are the leading causes of death and 
disability in the United States, accounting for 70 percent of deaths and affecting the quality of 
life of 125 million Americans, 65 percent of whom are over 65 years Medical comorbidity 
is prognostic of poor rehabilitation in geriatric patients, malung this disproportionately affected 
population ever more dependent on an already strained Medicare 
While successful treatments for symptoms exist, chronic conditions are rarely completely 
cured.9 A recent study by van Dijk et all0 documents the predictive nature of chronic conditions 
in elderly mortality but notes the lack of information on the synergistic effects of these diseases. 
The simultaneous treatment of multiple chronic conditions and underlying causative factors can 
be problematical for physicians due to the increased risk of adverse drug interactions during 
polypharmacy. 11.12,13 For this reason quality of care for chronic illnesses has become a more 
difficult challenge for physicians, as well as a matter of recent public concern.I4 
According to the Virginia Department of Health (vDH)'~, an accumulation of risk factors 
and a lack of prevention persist in mature Virginians. Chronic disease risk factors like poor 
nutrition, physical inactivity, failed prevention and improper care of existing conditions are 
linked to an increased length of hospital stay, treatment charges and mortality in ~ i r ~ i n i a . ' ~ , "  
Unhealthy diet and sedentary lifestyle are also prevalent in over 70 percent of Virginia's 
population. Overweight and obesity rates have risen for 15 years and contribute to cardiovascular 
disease (CVD), coronary heart disease (CHD), stroke, diabetes, hypertension, arthritis and some 
18,19.20 cancers. Twenty-six percent-of Virginians are hypertensive and 3 1 percent have high 
cholesterol, increasing their risk of stroke, kidney failure, and C H D . ~ ~  Men reported smoking, 
drinking, and being overweight while women reported a lack of physical activity. Blacks were 
more often hypertensive, diabetic and obese while Whites more often had high cholesterol.19  he 
VDH reports that comorbid cardiovascular disease, cancer, diabetes, renal disease, arthritis and 
depression are distinct threats to the health of Virginia's elderly.2' 
Cardiovascular disease disproportionately affects Blacks and those over 65.22 In Virginia, 
CVD caused over 126,000 hospital admissions and over 35 percent of all deaths in 2002. While 
precipitating factors remain unknown in more than 40 percent of the cases,23 studies have found 
that chronic obstructive pulmonary disease (COPD), diabetes, CHD, hypertension and renal 
insufficiency are common comorbidities to CVD and each ~ t h e r . ~ ~ , ~ *  CHD and hypertension are 
the most common etiologies in the elderly and often coexist with valvular heart disease, 
depression and dementia.".26 
Cancer has remained the second leading cause of death in Virginia since 1950. 
Approximately 65,000 Virginians died of cancer from 1997 to 2001. 27 Cancer caused over 
27,000 hospitalizations costing $670 million in 2002.~' Arthritis, diabetes, obesity, hypertension 
and depression are all well-documented cancer comorbidi t ie~ .~~ 
The national prevalence of diagnosed diabetes, which is expected to double by 2 0 5 0 , ~ ~  
increased 47 percent from 1997 to 2002 across all sexes, ages and races. These rates were higher 
in males and Blacks in every age In 2003 diabetes was the seventh leading cause of 
death in Virginia. Over 385,000 Virginia adults are diabetic, causing over 11,600 hospitalizations 
in 2002.~' Seventy percent of diabetes-related deaths are due to a comorbid cause (e.g. CVD, 
hypertension, obesity and overweight, and renal disease). 
Chronic renal disease (CRD) is prevalent in the aging population and is associated with 
hypertension, smoking, hypercholesterolemia and obesity. Aging, poor nutrition, diabetes and 
CVD are coexisting predictors for patients with end-stage renal disease (ESRD) and contribute to 
the increased progression of CRD and its comorbid complications.3'~32 In older CRD patients 
heart disease risk factors are strongly associated with risk of death from CVD.'~ 
Arthritis affects approximately 25 percent of adult Virginians and 55 percent of those 
over Depression increases the risk of mortality in rheumatoid arthritis (RA).;~ Systemic 
inflammation due to CHD is the major cause of vascular comorbidity in R A . ~ ~  
Depression is a strong determinant of d i s a b i ~ i t ~ . ' ~  up to 65 percent of myocardial 
infarction patients, 25 percent of cancer patients and 27 percent of stroke patients suffer from 
depression. Substance abuse disorders are prevalent in depressive patients.37 It is comorbid with 
both psychiatric and medical illnesses and is prevalent among diabetics, most often in the 
presence of comorbidities such as coronary artery disease (CAD), chronic arthritis and stroke." 
The literature on chronic disease comorbidity is limited. The numbers and trends 
reviewed here are helpful in the discussion of singular chronic disease but fall short of a 
comprehensive description on the state of chronic comorbidity in Virginia. This investigation is 
designed to analyze current frequencies and trends in order to provide a clearer picture of the 
prevalence of chronic diseases in Virginia's mature adults. 
It is projected that for certain conditions specific demographics, notably age, will be 
predictive for comorbidity. Findings are expected to confirm the coexistence of previously 
documented comorbidities (e.g. diabetes with obesity, CVD with hypertension and 
hypercholesterolemia, cancer with depression, and liver disease with alcohol abuse) as well as 
less documented comorbidities (e.g. certain conditions with neurodegenerative conditions, 
psychoses or substance abuse). 
Objectives 
The primary purpose of thlcspaper is to present prevalence and trend patterns of 
comorbidities in Virginia's over 45 population utilizing two years (2001 and 2004) of hospital 
discharge data. The data analysis includes diagnostic results on more than 1.5 million patients, 
information on the presence of up to seven different chronic comorbidities, and statistics on 
thirty different chronic conditions that may constitute these seven comorbidities. 
Another objective is to report the frequency and location of the outcome variables (seven 
comorbidities and thirty constituent conditions) in the patient population. As a corollary, this 
project categorizes the prevalence of chronic disease comorbidity by patient demographics (sex, 
age, race and location) and presents trends in this data for years 2001 and 2004. 
A third objective was to describe any associations of the outcome variables with each 
other as well as with selected demographic variables. 
Methods 
Study Populatiolz - .  
Patient-level data, obtained from Virginia Health Information (VHI), included every 
hospital discharge in Virginia during all four quarters of 200 1 (835,053 discharges) and for the 
first three quarters of 2004 (652,104 discharges). After exclusions in the age, race and location 
categories to remove unknowns and obtain the target population (aged 45 and older), the final 
sample size was N = 823,336 (n200, = 458,593 and n2004 = 364,743). 
Study Variables 
Demographic variables of interest were analyzed to relate the number and type of 
diagnoses to gender, age, race and location. The calculation of age in years is based on date of 
birth and date of hospital admission. The age variable excludes those less than 45 years old and 
was recoded into decades (45 to 54,55 to 64,65 to 74,75 to 84, and 85 and over) due to 
previous research that shows chronic conditions tend to increase with age.4.5,3 Race categories 
were collapsed into White, Black and Other (comprised of Asians, American Indians and 
Hispanics) due to relatively lower numbers of these latter groups. Health Planning Regions 
(Northwestern, Northern, Southwest, Central, and Eastern Virginia) are designated by the 
Virginia Department of Health. Up to nine diagnoses and up to seven comorbidities per patient 
were recorded. 
The VHI data set categorizes seven chronic comorbidities: Cancer (CCA), 
Cardiovascular Disease (CCV), Liver Disease (CLV), Renal Disease (CRN), Diabetes (CDI), 
Pulmonary Disease (CPO), and Cerebrovascular Degeneration (CCE). These comorbidities are 
defined by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD- 
9-CM) diagnostic codes and diagnoses related group (DRG) codes. These definitions can be 
found in Appendix A Table A. If a diagnosis field (primary or secondary) contains a value 
falling within the prescribed code ranges, the presence of that chronic comorbidity is indicated 
by a "1" (its absence is indicated by-a "Om), thus allowing analysis of a dichotomous ~ar iable . '~  
Since outcomes due to comorbidities vary among patients, simplification into an index of 
only seven comorbidities could result in loss of information. Thus to control for a broad array of 
underlying preexisting conditions that comprise these comorbid illnesses, a previous study16 
developed a comprehensive set of 30 comorbidity measures (CHF, Valvular Disease, Pulmonary 
Circulation Disease, Peripheral Vascular Disease, Liver Disease, Peptic Ulcer Disease, Chronic 
Pulmonary Disease, Paralysis, Neurological Disorders, Diabetes, Hypothyroidism, Renal Failure, 
AIDS, Lymphoma, Metastatic Cancer, Tumor, Rheumatoid Arthritis, Coagulopathy, Obesity, 
Weight Loss, Fluid and Electrolyte Disorders, Chronic Blood Loss Anemia, Deficiency 
Anemias, Alcohol abuse, Drug abuse, Psychoses, Depression, and Hypertension). These 
conditions were analyzed in conjunction with the seven comorbidities to find any correlations. 
Statistical Analysis 
A goal of this study was to describe the prevalence and location of the outcome variables 
(seven comorbidities and thirty constituent conditions) in the Virginia population. A second goal 
was to describe any associations of the outcome variables with each other as well as with 
selected demographic variables. 
Comorbidity Software 3.0, obtained from the Agency for Healthcare Research and 
Quality (AHRQ) and SPSS 13.0 were used to conduct all statistical analyses. Frequencies and 
proportions were calculated by discharge year for the variables: age, sex, race, health planning 
region (HPR), number of unspecified diagnoses (0 to 9), the number of comorbidities present (0 
to 7), and the thirty constituent conditions developed by Elixhauser et a1.16 
A Pearson chi-square test was performed on the categorical variables (age, sex, race, 
HPR, number of diagnoses and number of comorbidities) as well as the outcome variables (each 
of the seven comorbidities and each of the thirty component conditions) to test whether the 
observed differences in proportiofis between the two study groups (2001 and 2004) were 
statistically different. T-tests compared the mean ages, number of diagnoses and length of 
hospital stay of the study groups by year. The mean number of comorbidity diagnoses was 
analyzed over age, race, sex and HPR variables to observe its distribution in the population. 
The seven chronic comorbidities were analyzed for changes over time with respect to 
age, sex, race and HPR. Chi-square analysis was applied to find significant differences in the 
observations. Binary logistic regression, which included each of the categorical variables (age, 
sex, race, HPR and year), produced odds ratios (ORs) and 95% Confidence Intervals (CIS) for 
the description of how each category (e.g. decade bracket) of each demographic variable (e.g. 
age) contributed to each outcome comorbidity. This method serves to find key contributors while 
controlling for other confounding demographic variables. 
In this study, an OR is the ratio of the odds of a comorbidity's occurrence when a specific 
risk factor (or demographic category) is present, to the odds of the comorbidity's occurrence 
when the risk factor is absent. Intra-group comparisons were made by utilizing the lowest 
average prevalence of all seven comorbidities for a variable to select a reference group (reference 
OR=l). Any deviation represents an increase (OR>l) or decrease (OR<l) in risk as compared to 
the reference category. An OR is deemed not significant if its 95% CI contains 1. 
The same regression was repeated with the thirty constituent conditions to find which of 
these conditions contribute to each of the chronic comorbidity outcomes. In conjunction with the 
prevalence data for these conditions it was hoped to accurately characterize the state of a number 
of comorbidities in Virginia's patients. Because most diagnosed comorbidities were found to 
significantly increase from 2001 to 2004 and due to the fact that current data is more useful for 
policy implications, the year 2004 was chosen for binary regression. 
Results 
- .  Descriptive Statistics 
The distribution of patients in 2001 and 2004 according to the variables of age, sex, race, 
HPR, number of diagnoses and number of comorbidities are shown in Table 1. For both years, 
the majority of the patient population was comprised of Virginians aged 65 to 84 (over 47%), 
females (56%) and Whites (over 77%)). Most of the patients in both 2001 and 2004 are from the 
Southwest and Eastern regions (over 44%), have nine diagnosed conditions (over 32%) and one 
chronic comorbidity (over 40%). The results of the Pearson chi-square test on these variables are 
displayed in Table 1 with corresponding p-values. With the exception of sex, chi-square values 
were large for all study variables, ranging from 81.08 for HPR to 10,5 10.53 for number of 
diagnoses. All p-values were significant with the exception of the sex. 
Notable differences between the 2001 and 2004 patient populations follow. There was a 
1.5% shift of patient discharges from those over 65 to those aged 45 to 64, representing a slight 
mean age decrease from 68.2 to 67.9 (p <0.0001). The number of Blacks and Others discharged 
increased slightly. Length of hospital stay increased (p <0.0001). The mean number of diagnoses 
decreased slightly (p <0.0001) while the mean number of comorbidities increased in every 
category from 2001 to 2004. There was a consistent increase in mean number of comorbid 
diagnosis with age, males and Blacks. The western parts of the state had the highest mean 
diagnoses both years. Table 2 carries data on mean comorbidity diagnoses. 
Cornorbidity and Constituent Condition Trends 
Five of the seven chronic comorbidity diagnoses increased at a significant level from 
2001 to 2004 (Table 3). Diagnoses of chronic cardiovascular disease (CCV) had both the largest 
prevalence (nearly 40% both years) and increased 1.8%. Chronic pulmonary disease (COP) 
exhibited the second highest prevalence both years, increasing 1.7% to 19.6% in 2004. Chronic 
cerebrovascular degeneration (CCE) and chronic liver disease (CLV) both increased 0.3% to 
8.2% and 1.9%, respectively, in 2004. Chronic renal disease (CRN) increased almost 1% to 6.7% 
in 2004. Cancer (CCA) remained constant at 7.4% while chronic diabetes (CDI) decreased from 
6.4% to 5.8%. 
Twenty-two of the thirty constituent conditions increased at a significant level from 2001 
to 2004 (Table 3). The largest increases included hypertension (4.3%), electrolyte disorders 
(2.2%), fluid and chronic pulmonary disease (1.7%) and depression (1.2%). Diagnoses of liver, 
pulmonary circulation and peripheral vascular diseases, as well as paralysis, all slightly 
decreased at a significant level (p<0.05). In 2004 the most prevalent diagnoses were 
hypertension (50%), COPD (20%), diabetes without chronic complications (19%), fluid and 
electrolyte disorders (19%) deficiency anemias (10%) and CHF (10%). These conditions 
accounted for the largest increases in the three year period. 
Comorbidity Trends by Demographic Variables 
Tables 4 to 10 present chi-square analysis on each of the seven diagnosed comorbidities 
categorized by demographic variables, with notable changes as follows. CCA (Table 4) 
decreased 0.4% in Blacks (p=0.0074) and increased 0.3% in the Southwest HPR (p=0.0044). 
CCV (Table 5) increased significantly across all categories of all demographics (p<0.0001), the 
largest increases being in those aged 85 and over (3.5%), males (2.2%), Blacks (2.5%) and the 
Central HPR (2.3%). CLV (Table 6) increased mostly in ages 45 to 74 (p<0.0001), both sexes, 
non-Whites and all HPRs except for Central. CRN (Table 7) showed significant increases 
(p<0.0001) in patients aged 65 and older, both sexes, Whites, Blacks, and in all HPRs except for 
Northwest. CDI (Table 8) decreased approximately 1.0% (p<0.0001) in the 55 to 64 age group, 
females, Blacks and in Central Virginia. COP (Table 9), rose in all demographic groups except 
Other, increasing approximately 2.0% in the 45 to 54 age group, females, Whites and in 
Southwest Virginia (p<0.0001). CCE (Table 10) increased less than 1.0% in the 45 to 64 age 
group, females, Whites, and Northem, Central and Southwest HPRs. 
Regression Analysis: Comorbidity and Demographic Categories 
Binary logistic regression was used to describe the contribution of the demographic 
variables (year, age, sex, race and HPR) to each diagnosed comorbidity. The odds ratios (and 
corresponding 95% CIS) are reported in Table 1 1. Odds ratios greater than 1 .O indicate a higher 
risk of a comorbid diagnosis for a certain demographic category. 
In reference to 2001, being discharged in 2004 was found to be slightly protective for 
CCV, CDI, and COP and to increase risk for CLV, CRN and CCE. As compared to the 45 to 54 
decade, all ages 55 to 74 showed increased risk for CCA, CRN, CDI, and CCE. The 85 and over 
age group had a higher risk for CCE diagnosis (OR=5.86, CI: 5.68-6.03). 
Males, as compared to females, showed increased risk for CCA (1.39; 1.75-1.85), CLV 
(1.67; 1.61-1.73) and CRN (1.33; 1.30-1.33, and are most protective for CCV (0.62; 0.61-0.63). 
Black and Other groups, as compared to White, showed increased risk for all 
comorbidities with the exception of CCE and CLV. The highest risks in the race category were 
seen with CRN: OR=3.13 for Blacks (CI: 3.07-3.20) and OR=2.07 for Other (CI: 1.93-2.21). 
Results varied by region. As compared to Northern Virginia, all HPRs revealed a slightly 
increased risk for CLV and, with the exception of the Central region, for CRN and CDI as well . 
All HPRs except for Central were found mildly protective for CCA, CCV, COP and CCE. 
Regression Analysis: Comorbidity and Constituent Conditions 
Binary logistic regression was used to describe the individual contribution of each 
constituent condition to risk of each diagnosed comorbidity. Table 12 reports the prevalence (and 
corresponding ORs with 95% CIS) of patients in 2004 with a diagnosed comorbidity that are also 
diagnosed with one or more constituent conditions. 
Due to the nature of this comparison, some diagnoses codes coincided (e.g. CDI and 
diabetes or CLV and liver disease). This occurrence produced very large ORs (italicized in Table 
12) as they represent the same diagnosis for both the condition and comorbidity. 
CCA coincided with coagulopathy (OR=2.52; 2.28-2.79), weight loss (OR=1.65; 1.46- 
1.87), deficiency anemias (OR=1.72; 1.60-1.85), and fluid and electrolyte disorders (P=9.6%, 
OR=1.21; 1.13-1.29). 
CCV patients had the highest number of coexisting conditions, as evidenced by a 
comorbid prevalence range of 20.0% (drug use) to 64.2% (valvular disease). Conditions that 
increased risk for CCV included peripheral vascular disease (P=58.4%, OR=1.94; 1.88-2.00), 
valvular disease (P=64.2%, OR=1.58; 1.51-1.65), chronic pulmonary disease (P=51.5%, 
OR=1.59; 1.56-1.62), diabetes (P=48.9%, OR=1 .SO; 1.48-1.53), renal failure (P=57.8%, 
OR=1 .SO; 1.45-1.55), coagulopathy (P=44.9%, OR=1.26; 1.2 1- 1.32) and hypertension 
(P=43.6%,OR=1.25; 1.23-1.27). 
CLV coincided with diabetes (OR=1.41; 1.29-1.55), weight loss (OR=1.34; 1.14-1.59), 
fluid and electrolyte disorders (OR=1.60; 1.47-1.73), chronic blood loss anemia (OR=1.41; 1.61- 
1.70), deficiency anemias (OR=l. 13; 1.01-1.27), and alcohol abuse (0R=13.34; 12.14-14.65). 
Risk for CRN was increased by valvular disease (P=10.2%, OR=1.16; 1.02-1.32), 
peripheral vascular disease (P=12.2%, OR=1.32, 1.18-1.48), AIDS (P=14.8%, 0R=2.86, 1.54- 
5.31), lymphoma (P=10.5%, OR=1.73; 1.31-2.28), fluid and electrolyte disorders (P=10.6, 
0R=2.69; 2.52-2.87), and deficiency anemias (P=14.2%, OR=2.67; 2.48-2.89). 
Risk for CDI diagnosis was increased by CHF (P=9.8%, OR=1.33; 1.23-1.44), peripheral 
vascular disease (P=11.9%, OR=1.25; 1.13-1.37), renal failure (P=23.3%, OR=2.41; 2.22-2.62), 
liver disease (OR=1.29; 1.09-1.54), obesity (OR=l. 10; 1.01- 1.21), fluid and electrolyte disorders 
(OR=1.29; 1.21-1.38), and drug abuse (OR 1.49; 1.16-1.91). 
COP was diagnosed with rheumatoid arthritis (P=19.9%, OR=1.36; 1.11- 1.16), 
deficiency anemias, drug abuse and-depression. 
CCE coincided with neurological disorders (P=29.2%, 0R=5.94; 5.69-6.20), 
hypothyroidism (P=l1.3%, OR=1.50; 1.43-1.57), weight loss (OR=1.42; 1.3 1-1.52), fluid and 
electrolyte disorders (OR=1.53; 1.48-1.58), chronic blood loss anemia, deficiency anemia, 
depression (OR=1.37; 1.30- 1.44) and hypertension. 
Discussion 
Descriptive Analysis - .  
Denzographic Trends 
Fifty-eight percent of Virginia discharges in 2004 had one or two comorbid chronic 
conditions, with a small increase from 2001. This increase is predicted by previous national and 
4.18.19 state trends and highlights the importance of studying comorbidities in depth. In reference 
to discharges trends (Table I), fluctuations in age, race and regional demographics were slight 
and likely due to normal population ebb and flow. Mean comorbidity diagnoses increased by 
age, as predicted by previous s t u d i e ~ . ~ ~ ~ . ~  
Most hospital discharges come from Southwest and Eastern Virginia. These two regions 
are comprised of many rural and comparatively lower socioeconomic areas of the state. It 
follows that the Southwest and Eastern HPRs are the first and third ranked regions for mean 
chronic disease comorbidity diagnoses, respectively. Possible explanations for this result include 
a lack of access to primary or specialized care, deficiencies in prevention and education and the 
lack of proper care for chronic  condition^.^ ~ h e s e  areas constitute important candidates for 
continued attention from a health policy standpoint. 
Comorbidity Trends 
Increases occurred in all comorbidity diagnoses with the exception of cancer (CCA) that 
stayed constant, and diabetes (CDI) that decreased. While cancer remains a major killer of 
Virginians, prevention and treatment has been established, if not maximized, over the past fifty 
years, explaining this constant prevalence.27 The decrease in CDI could be the result of a recent 
increase in attention from public and private sector in conjunction with obesity. More extensive 
trending analysis is required, however we cannot exclude the possibility that Virginia is moving 
in an unhealthy direction and that preventive medicine strategies still require attention. 
Variation existed in the comorbidity analysis with respect to demographics. All with the 
exception of CCE were found to have a higher prevalence in males. Trending data presented here 
for CCA, CCV, CRN, COP and CCE support previous findings that these comorbidities increase 
with age,".' while CLV and CDI revealed just the opposite. Possible explanations include the 
known linkage between liver disease and diabetes and that diabetes is rapidly increasing in 
younger ages. Regression analyses agree with these findings (CLV was the least prevalent of all 
comorbid diagnoses; CDI did not increase in any demographic). 
CCV showed expected increases across all demographic variables (almost 2%) due to its 
multitude of comorbid conditions and pervasive nature in the population. CRN also showed 
increasing prevalence in most demographics, with larger increases in prevalence seen in Blacks 
and older age groups. Renal disease is comorbid with hypertension, a prevalent condition in 
~ l a c k s . ' ~  CDI only increased in the Other race category, albeit not significantly. However, it 
should be noted that while diabetes is may be coming under control in Virginia (decreasing 
across all age groups) it still disproportionately afflicts minority races as compared to 
Odds ratios revealed there is a significant increased risk to Blacks for CDI, CRN and CCE. 
COP increased in all demographics. Like cardiovascular disease, it is prevalent in all 
areas. Coexisting diagnoses included arthritis, deficiency anemias, drug abuse and depression. 
Arthritis and depression are known comorbidities to COPD, but the drug abuse diagnosis is an 
interesting finding as it is known that greater risks exist for medical comorbidities in persons 
with addictive disorde~-s.~' 
CCE primarily affected the elderly and females. The slight increase of cerebrovascular 
degeneration could be a result of the decreasing 85 and over demographic, the category in which 
it had the highest prevalence. While its prevalence did increase significantly across multiple 
categories, this condition does not seem to be one that is entirely preventable. Because age is 
such a strong predictor (OR=2.76 for patients ages 75 to 84 and OR=5.86 for patients 85 and 
over), this comorbidity is a good candidate for emphasis on treatment education as part of a 
regimen for other comorbid conditions that may include depression, hypertension, weight loss, 
anemias, fluid and electrolyte disorders and hypothyroidism. 
Demographic Predictors of Comorbidity Risk 
Age is the primary predictor for CCA comorbidity, as revealed by regression analysis. 
Race groups (Black and Other) are major predictors for CCV, CRN, COP and CDI diagnoses. 
Sex, race and HPR all contribute to CLV comorbidity. Race and age together predict principally 
for CRN and CDI comorbidity. Age (specifically those over 75) is a principal predictor of CCE 
comorbidity. Chronic comorbidities were more often found in the Southwest, Eastern and 
Northwest regions. This information may be useful in chronic disease prevention strategy. 
Increasing the accuracy of forecasts of chronic disease comorbidity can help healthcare providers 
as well as government officials put resources to good use for maximized health outcomes. 
It is also interesting that barring the obvious trends, chronic comorbidity affects both 
sexes, all races and all ages. There were no clear cut findings that support that, for example, 
Blacks had a much higher prevalence of diabetes or cardiovascular comorbidity. This study 
expected to find demographics to be more precise predictors of morbidity. 
Constituent Predictors of Comorbidity Risk 
Table 12 revealed that at least four and as many as eight constituent conditions were co- 
diagnosed with each chronic comorbidity. CHF, valvular disease, peripheral vascular disease, 
uncomplicated diabetes, renal failure, AIDS, rheumatoid arthritis, coagulopathy, weight loss, 
fluid and electrolyte disorders, deficiency and blood loss anemias, drug abuse, depression and 
hypertension were all diagnosed along with at least two chronic comorbidity diagnoses. 
Deficiency anemias and fluid and electrolyte disorders were found diagnosed with five of the 
chronic comorbidities. This type of analysis is important because it reveals the higher prevalence 
of specific underlying factors in each comorbidity diagnosis, and thus reveals which conditions 
deserve more attention from the medical community. 
What is most interesting about this OR data is not the presence or absence of expected 
comorbidities but the reporting of new or less studied chronic coexistences due to their 
importance to current and growing comorbid trending.I6 ~ o s t  notable is the above mentioned 
fluid and electrolyte disorder, found to be predictive of multiple comorbidities including CRN 
(0R=2.69), CLV (1.6), CCE (1.53), CDI (1.3) and CCA (1.21). Deficiency anemias predict for 
CRN (2.67), CCA (1.72), CCE (1.47), and CLV (1.13). Weight loss revealed increased risk for 
CCA (1.65), CLV (1.34) and CCE (1.42). These common predictive values present another area 
for future research expanse. The highest correlation in the regression analysis was alcohol use 
predicting risk for CLV diagnosis at 0R=13.34, which is intuitive. 
Limitations 
This study reports results for hospitalized Virginians only. Multiple discharges of the 
same patient are inherent to this dataset and thus prevalence data may not be accurate for the 
patient population. It is not believed that this fact weakens this study, however, because the 
purpose of this project was to use this population of patients to estimate comorbidity and the 
occurrence of underlying conditions. Excluding repeated diagnoses or discharges may be useful 
in a future study. In addition, using the entirety of the 2004 data set and having a larger gap in 
years in which to study trends would be beneficial. 
While reviewers deemed the statistical methods used in this study to be appropriate, other 
tests may also be suitable. For example, due to the small prevalence of comorbidities and 
scewness caused by lopsided group proportions, a Poisson regression rather than a logistic 
regression might be more appropriate. Instead of categorizing age into decades as i t  was 
presented here, the age variable could be left as a continuous variable for regression analysis. 
Future studies may see theknefi t  in the development of comorbidity matrices that take 
into account multiple confounding conditions as well as allowing for the study of interactions so 
as to accurately analyze the cornorbid nsk to certain individuals. If this analysis could be 
expanded to include behavioral and social risk factors, a powerful predictive model for mortality 
and morbidity due to chronic cornorbid conditions may be feasible. 
Conclusion 
The results presented in this-report concur with VDH dataI5 indicating that despite certain 
improvements, Virginians continue to engage in high-risk behaviors and do not sufficiently 
employ preventive health practices. This data also supports previously documented correlations 
between many constituent conditions and chronic comorbidities as well as creates predictions for 
yet unstudied comorbidities. Innovation in all areas of this disease interaction is significant, not 
just for improved diagnoses, management or polypharmacy, but in research of new comorbidities 
and prediction models as well. 
Substantial variations in prevalence of chronic comorbidity across all demographic 
categories indicate a continued need to monitor these factors at the state and local levels. 
Continued regional-level assessment of progress toward reducing morbidity and mortality due to 
these conditions is equally important. Certain features in this report have the potential to be 
helpful indicators for assessing the effectiveness of state and local prevention programs to 
decrease chronic conditions in the Commonwealth. It is hoped that the comprehensive approach 
used in the report will be useful in addressing chronic illness in Virginia where Healthy People 
2010 goals are still works in progress.18 Trending results may provide data relevant for health 
care resource allocation purposes for future medical treatments and physical care. Future 
identification and classification of chronic risk factors will lead to insightful pathophysiology, 
help to direct prevention and increase the accuracy of individualized treatment models. 
The long-term care and cost required by chronic conditions continues to heavily impact 
health care in Virginia and the United States. Obtaining accurate information on how chronic 
comorbidities are influenced by demographic and disease risk factors should remain a high 
priority in policy, intervention and prevention arenas. 
Tables 
Table 1. Hospital Discharge Characteristics by Year 
2001 2004 Difference X2 p-value Variable 
N % N Yo ("10) 
TOTAL 458593 100.0 
Age 
45-54 91569 20.0 
55-64 91031 19.9 
65-74 11 1756 24.4 
75-84 113333 24.7 
85+ 50904 11.1 
Sex 
Male 202087 44.1 
Female 256476 55.9 
Race 
White 342670 78.4 
Black 88499 20.2 
Other 6022 1.4 
Health Planning Region 
Northwestern 72544 15.8 
Northern 65467 14.3 
Southwest 102790 22.4 
Central 89805 19.6 
Eastern 102886 22.4 
Number of Diagnoses 
1 13893 3.0 
2 24360 5.3 
3 36142 7.9 
4 45433 9.9 
5 50037 10.9 
6 49131 10.7 
7 46303 10.1 
8 44716 9.8 
9 148578 32.4 
Number of Chronic Comorbidities 
0 179912 39.2 
1 183566 40.0 
2 77764 17.0 
3 15923 3.5 
4 1394 0.3 
5 34 0.01 
6 0 0.0 
Table 2. Mean Comorbidity Diagnoses by Year 
Variable 2001 2004 




















Table 3. Prevalence of Comorbidities and Constituent Conditions 
Variable - 2001 2004 Diff. X2 p-value 
N O/o N % (%\ 
TOTAL 458593 100.0 364743 100.0 1 
Chronic Comorbidities 
Cancer (CCA) 
Chronic Cardiovascular (CCV) 
Chronic Liver (CLV) 
Chronic Renal (CRN) 
Chronic Diabetes (CDI) 
Chronic Pulmonary Dz (COP) 
Cerebrovascular Deg. (CCE) 
Constituent Conditions 
Congestive heart failure 
Valvular disease 
Pulmonary circulation dz. 
Peripheral vascular disease 
Paralysis 
Other neurological disorders 
Chronic pulmonary disease 
Diabetes wlo chronic compl. 













Fluid & electrolyte disorders 







Table 4. Cancer (CCA) Trends 
208-1 2004 Difference X~ Variable p-value 




















Table 5. Chronic Cardiovascular Disease (CCV) Trends 
2001 2004 Difference Variable x2 p-value 




















Table 6. Chronic Liver Disease (CLV) Trends 
200t 2004 Difference x2 p-value Variable 




















Table 7. Chronic Renal Disease (CRN) Trends 
2001 2004 Difference X2 Variable p-value 




















Table 8. Chronic Diabetes (CDI) Trends 
Variable 2001 2004 Difference X2 p-value 




















Table 9. Chronic Pulmonary Disease (COP) Trends 
Variable 2001 2004 Difference x2 p-value 




















Table 10. Chronic Cerebrovascular Degeneration (CCE) Trends 
2001 2004 Difference Variable x2 p-value 




















Table 11. Comorbidities Predicted by Demographic Variables 
Variable CCA 
OR 95% CI 
Year 





OR 95% CI OR 95%CI 
3 QQ 1.110 
2004 1.00 0.98 1.02 
Age 
45-54 1 ,00 





0.09 0,#7 0,91 
1 .M) 
I 1.39 l.a7 
1.43 1.59 7,47 
1.02 D.93 T?D5 
0 0,49 0,W 
0.96 0.95 0.981 
1 ,OD 
T .QO 
t,93 r.89 1.98 
1,3Q 1,312 1,aO 
f .CIS 1.01 1 
0.37 0.W 0.92 
0-48 0.47 0.49 
COP CCE 
Q,B@ O,#T 0,$9 
1.00 
B.PS2 0.67 0,83 
0.47 0.46 0.47 
8.47 0.44 0,48 
0,61 0.59 0.62 
0.88 QB5 0.87 
1 ,OD 
t .CiB 
1,32 1.30 134 
2,05 1-92 2,lW 
0.84 0.BZ 0.86 
OR 9 W C I  
1.00 
1,06 l.m 1.08 
1.00 
0.M 0,81 B,08 
7-15 1 . 1  1.19 
2.m 288 284 
5,86 5.68 6.93 
0.82 0,81 4.84 
1 ,OD 
1 .W 
1,31 1.23 1,33 
0.70 il.6rl 0.76 
0.98 0.95 1.01 
,00 1 1,Ob 
1,21 I 125 0.59 0.67 0.70 
0.91 a . ~ a  11.94 o . 7 ~  a n  0.31 
to3 099 1 ,06 D,$D 0.78 0.82 
. -  L ---- 
T.lB 1.14 1.22 
1.06 
0.BEi 0.H 0.m 




0.96 0.93 D.90 
1134 0-91 0.97 
2,91 0 888 0,- 
- -  - 
t.14 1-12 l , t 6  
1,m 
1-43 1.39 1.4B 
0 . 6  0.43 0.47 
2 0 .  0 . a  
I 0 . 1  0.13 
1 I 1.73 
1 -00 
C .OO 
0.37 0.B7 0.95 
q.64 147 1-R3 
75-84 1.5.9 1-55 1 . 6  
85+ 1,15 1 10 I 
Sex 
Male 1 .  1,36 1 4  
Female 1 .WI 
Race 
Wh~te I .HI 
Black 1.02 1.00 1 5  
Other 0 , s  0,09 1.03 
HPR 
Northwestern 6.95 0.93 0.99 
Northern 1 .UU 
Southwest 0 .E  033 Q,M 
Central 1.m 0.99 1-05 
1.73 1.M 1.30 
1 I 1,83 
1 1.W 1 .  
7-33 I 1.35 
1. 00 
f .QO 
3.13 3-07 3.M 
2.07 1 2.21 
1 0.19 0.19 
0.15 0.15 O,15 
0.62 0.61 0 .  
1 .La 
1 .Oil 
7 - 0 8  1.07 1.18 
128 1 I 
O.FdI3 U.M D.91 
7 
0.W 0-83 0-W 
a.00 0.98 1-02 
Eastern 0.95 0.92 0.48 . 
T.17 1 125 
I am 
7 1 1-24 
0.92 0.w a 94 1,20 7.13 1 23 
1.13 1.09 1.18 
f ,OD 
t,13 1.09 1.17 
r,aa 0.97 1 
- -  
1.03 1 1  1-15 0.96 0.93 0.951 








Solid tumor w/out metastasis 
Rheumatoid arthritis 
Cancer (CCA) Condition 
Prev OR 95% CI 
Congestive heart failure 6.5 0.76 0.69 0.84 
Valvular disease 6.6 0.71 0.60 0.82 
Pulmonary circulation disease 4.4 0.57 0.39 0.82 
Peripheral vascular disease 4.2 0.50 0.43 0.59 
Paralysis 5.5 0.49 0.39 0.62 
Other neurological disorders 6.3 0.32 0.26 0.40 
Chronic pulmonary disease 8.0 0.64 0.60 0.69 
Diabetes w/o chronic compl. 5.5 0.80 0.75 0.86 
Diabetes w/ chronic compl. 3.3 0.45 0.37 0.54 
Coagulopathy 
Obesity 
Liver Disease (CLV) 
Prev OR 95% CI 
1.70 0.96 0.85 1.09 
1.60 0.74 0.61 0.91 
2.10 1.31 0.91 1.88 
0.70 0.53 0.42 0.66 
0.60 0.42 0.30 0.59 
1.60 0.72 0.59 0.87 
1.60 0.73 0.67 0.80 
2 . 0 0  1.41 1.29 1.551 
1.80 1.09 0.92 1.31, 
Cardiovascular Disease (CCV) 
Prev OR 95% CI 
99.3 282 -- -- 
Weight loss 13.8 
Fluid & electrolyte disorders 9.6 
Chronic blood loss anemia 8.7 
64.2 
61.6 
1.58 1.51 1.65 
1.04 0.95 1.14 
1.65 1.46 1.87 
1.21 1.13 1.29 
1.13 0.96 1.32 
:::: pi 38.3 0.74 0.70 0.77 42.5 0.94 0.92 0.96 
58.4 1.94 1.88 2.00 
38.5 0.89 0.85 0.93 
34.7 0.68 0.65 0.70 




1.59 1.56 1.62 
1.50 1.48 1.53 
1.24 1.19 1.29 
1.72 1.60 1.85 
Alcohol abuse 4.1 0.35 0.28 0.43 
Drug abuse 2.4 0.33 0.22 0.48 
Psychoses 4.6 0.65 0.53 0.79 
Depression 5.0 0.57 0.50 0.65 
Hypertension 5.3 0.58 0.55 0.61 
43.2 0.90 0.85 0.95 
40.6 0.90 0.87 0.92 
a Boxes represent statistically significant results 
b Italicized results have high ORs due to overlapping or identical ICD-9-CM diagnosis definitions for both Comorbidity and Condition 
4.20 
2.20 1.13 1.27 
25.1 0.59 0.56 0.62 
20.0 0.48 0.44 0.52 
27.2 0.55 0.52 0.58 
31.0 0.66 0.64 0.68 
43.6 ( 1.25 1.23 1.27 
16.00 13.34 12.14 14.65 
4.30 0.14 0.1 1 0.17 
2.00 0.83 0.67 1.04 
1.60 1.04 0.90 1.20 
1.2 0.55 0.51 0.59 
Table 12. Cont'd. 2004 Comorbidities Predicted by Constituent Conditions 
Condition 
Congestive heart failure 
Valvular disease 
Pulmonary circulation disease 
Peripheral vascular disease 
Paralysis 
Other neurological disorders 
Renal Disease (CRN) I Diabetes (CDI) 
Chronic pulmonary disease 7.00 0.90 0.84 0.97 1 5.3 0.8 0.79 0.90 
Prev OR 95% CI 
15.20 2.86 2.66 3.09 
10.20 1 1.16 1.02 1.32 
8.50 1.10 0.84 1.43 
12.201 1.32 1.18 1.48 
5.10 0.82 0.66 1.02 
5.10 0.42 0.35 0.51 
Diabetes w/o chronic compl. 6.80 1.02 0.94 1.12 ( 7.1 39.6 36.27 43.34 
Prev OR 95% CI 
9.8 1 1.3 1.23 1.44 
5.4 1.1 0.91 1.22 
5.0 0.6 0.44 0.82 
11.91 1.2 1.13 1.37 
5.8 1 .O 0.88 1.20 
3.9 0.8 0.70 0.97 
Diabetes w/ chronic compl. 35.90 16.69 15.50 17.98 / 96.9 14472 -- -- 
Peptic ulcer Disease 5 . 0  0.96 0.25 4 5.1 0.5 0.12 2.07 
AIDS 14.80 2.86 1.54 3.9 0.9 0.40 2.19 
Hypothyroidism 4.60 0.94 0.83 1.06 
Renal failure 96.6 6E+03 -- -- 
Liver disease 9.90 0.95 0.77 1.17 
4.6 0.9 0.86 1.04 
23.3 
6.6 
Lymphoma 10.50 1 1.73 1.31 2.28 
Metastatic cancer 3.70 0.67 0.54 0.82 
Solid tumor w/out metastasis 4.90 0.89 0.72 1.1 1 
Rheumatoid arthritis 5.50 1 1.21 1 .OO 1.48 
Coagulopathy 10.20 1.10 0.95 1.29 
Obesity 4.30 0.98 0.85 1.14 
Weight loss 12.90 
Fluid & electrolyte disorders 10.60 
1.16 1.00 1.35 
2.69 2.52 2.87 
Chronic blood loss anemia 8.30 1.02 0.84 1.24 
Deficiency Anemias 14.20 1 2.67 2.48 2.89 
Alcohol abuse 2.90 0.64 0.51 0.79 
Drug abuse 4.80 0.75 0.54 1.04 
Psychoses 4.40 0.81 0.65 1.01 
Depression 2.90 0.65 0.55 0.76 
Hypertension 9.5 0.39 0.36 0.42 

Appendix A 
Table 13. Comorbidity Diagnoses-Codes 
Chronic Comorbidity 
Cancer (CCA) 
Cardiovascular Disease (CCV) 
Liver Disease (CLV) 





Pulmonary Disease (CPO) 
Cerebrovascular Degeneration (CCE) 
P 
ICD-9-CM Diagnosis Field Values 
and Ranges 
141.0 to 160.9; 
162.0 to 172.9; 
174.0 to 208.91 
412.0 to 414.9; 
426.0 to 429.1 
57 1.0 to 572.8 
582.0 to 583.9; 
585.0 to 587.0; 
403.01,403.11,403.9 1,404.02,404.03, 
404.12,404.13,404.92 or 404.93 
11 250.01; 
250.1 to 250.91 
496.0; 
491.0 to 493.91 
290.0 to 290.9; 
294.0 to 299.9 
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